R&D Trends

National Institute of Mental Health issues strategic plan for research

Thursday, March 26, 2015 02:57 PM

The National Institute of Mental Health (NIMH) has issued a new strategic plan for research. Informed by the successes and challenges of recent years, the new plan updates the strategic objectives of its 2008 predecessor with the aim of balancing the need for long-term investments in basic research with urgent mental health needs.

More... »


GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships

Thursday, March 26, 2015 02:54 PM

GlaxoSmithKline is encouraging academic scientists in Europe, Canada and the U.S. to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge—a program designed to accelerate the translation of early-stage research into game-changing new medicines. The challenge provides a new template for drug discovery as it seeks to rapidly uncover the best opportunities for discovery research.

More... »


Shire, Cincinnati Children's establish rare disease research collaboration

Thursday, March 26, 2015 02:37 PM

Shire and Cincinnati Children's Hospital Medical Center have announced a three-year, broad research collaboration for rare diseases. The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research experience.

More... »

Report: Antibiotics pipeline boasts 741 products, first-in-class development remains low

Wednesday, March 25, 2015 03:17 PM

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, said business intelligence provider GBI Research, a New York-based provider of business intelligence reports.

More... »

New Innovative Medicines Initiative project launched to combat carbapenem resistance

Wednesday, March 25, 2015 03:15 PM

Eighteen European academic partners and three pharmaceutical companies are launching a new project under the Innovative Medicines Initiative (IMI) funded New Drugs 4 Bad Bugs (ND4BB) program. COMBACTE-CARE (Combating Bacterial resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies and activities related to the treatment of patients with infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Being very difficult to treat and sometimes deadly, CRE are considered to be one of the most dangerous resistant bacteria in the world. University Medical Center Utrecht is the project’s managing entity.

More... »

Cancer Research U.K. partners with Engineering and Physical Sciences Research Council

Wednesday, March 25, 2015 02:59 PM

Cancer Research U.K. has partnered with the Engineering and Physical Sciences Research Council (EPSRC), the U.K.'s main agency for funding research in engineering and the physical sciences, to co-fund multidisciplinary research projects.

More... »

AstraZeneca, Harvard Stem Cell Institute to collaborate in diabetes

Wednesday, March 25, 2015 02:57 PM

AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

More... »

Calico, QB3 partner on biology of aging

Wednesday, March 25, 2015 02:53 PM

Calico, a California-based Google-founded R&D company, and QB3, a University of California institute advancing biotechnology innovation, have partnered to conduct research into longevity and age-related diseases. This innovative partnership will create and foster an interdisciplinary community of scientists in these fields.

More... »

Cold Spring Harbor Laboratory, GSK to develop diabetes and obesity therapeutic

Monday, March 23, 2015 03:40 PM

Cold Spring Harbor Laboratory (CSHL), based in New York, has inked a collaboration with GlaxoSmithKline to develop a treatment for obesity and type 2 diabetes.

More... »

Takeda, ImmunoGen partner

Monday, March 23, 2015 03:38 PM

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has licensed exclusive rights to use ImmunoGen's ADC technology—including ImmunoGen's new DNA-acting IGN payload agents—to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs